Patents by Inventor Ian Hardy

Ian Hardy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for immune cell modulation in adoptive immunotherapies
    Patent number: 11932870
    Abstract: Compounds that either produced a higher proportion or greater absolute number of phenotypically identified naive, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: March 19, 2024
    Inventors: Jonathan Rosen, Betsy Denise Rezner, Ian Hardy, Eigen Peralta
  • COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
    Publication number: 20220401487
    Abstract: Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.
    Type: Application
    Filed: July 8, 2022
    Publication date: December 22, 2022
    Inventors: Jonathan ROSEN, Betsy REZNER, Bahram VALAMEHR, Ryan BJORDAHL, Eigen PERALTA, Ian HARDY
  • Compositions and methods for immune cell modulation in adoptive immunotherapies
    Patent number: 11413309
    Abstract: Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: August 16, 2022
    Assignee: FATE THERAPEUTICS, INC.
    Inventors: Jonathan Rosen, Betsy Rezner, Bahram Valamehr, Ryan Bjordahl, Eigen Peralta, Ian Hardy
  • Optimized PNE-based chimeric receptor T cell switches and uses thereof
    Patent number: 11091546
    Abstract: Disclosed herein are chimeric antigen receptor effector cells (CAR-ECs) and CAR-EC switches. The switchable CAR-ECs are generally T cells. The one or more chimeric antigen receptors may recognize a peptidic antigen on the CAR-EC switch. The CAR-ECs and switches may be used for the treatment of a condition in a subject in need thereof.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: August 17, 2021
    Assignee: The Scripps Research Institute
    Inventors: Travis Young, David T. Rodgers, Ian Hardy, Chanhyuk Kim, Peter G. Schultz, Eric Hampton, Eduardo Laborda, Leonard Presta
  • COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
    Publication number: 20200181573
    Abstract: Compounds that either produced a higher proportion or greater absolute number of phenotypically identified naive, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.
    Type: Application
    Filed: December 4, 2017
    Publication date: June 11, 2020
    Inventors: Jonathan Rosen, Betsy Denise Rezner, Ian Hardy, Eigen Peralta
  • COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
    Publication number: 20200179451
    Abstract: Compounds that either produce a higher proportion or greater absolute number of phenotypically identified naive, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies, such as those providing improvements in one or more therapeutic outcomes, are provided.
    Type: Application
    Filed: July 19, 2018
    Publication date: June 11, 2020
    Inventors: Jonathan Rosen, Eigen Peralta, Ian Hardy, Betsy D. Rezner, Christian Maine, Daniel Shoemaker, David Robbins, Lucas Thompson
  • COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
    Publication number: 20190282618
    Abstract: Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.
    Type: Application
    Filed: January 20, 2017
    Publication date: September 19, 2019
    Inventors: Jonathan Rosen, Betsy Rezner, Bahram Valamehr, Ryan Bjordahl, Eigen Peralta, Ian Hardy
  • OPTIMIZED PNE-BASED CHIMERIC RECEPTOR T CELL SWITCHES AND USES THEREOF
    Publication number: 20190169289
    Abstract: Disclosed herein are chimeric antigen receptor effector cells (CAR-ECs) and CAR-EC switches. The switchable CAR-ECs are generally T cells. The one or more chimeric antigen receptors may recognize a peptidic antigen on the CAR-EC switch. The CAR-ECs and switches may be used for the treatment of a condition in a subject in need thereof.
    Type: Application
    Filed: April 15, 2016
    Publication date: June 6, 2019
    Inventors: Travis YOUNG, David T. RODGERS, Ian HARDY, Chanhyuk KIM, Peter G. SCHULTZ, Eric HAMPTON, Eduardo LABORDA, Leonard PRESTA
  • Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
    Publication number: 20080139604
    Abstract: A method of treating atherosclerosis is disclosed wherein nicotinic acid or another nicotinic acid receptor agonist is administered to the patient in combination with a DP receptor antagonist. The DP receptor antagonist is administered to reduce, prevent or eliminate flushing that may otherwise occur.
    Type: Application
    Filed: February 15, 2006
    Publication date: June 12, 2008
    Inventors: Shaun Fitzpatrick, Christian Seiler, Ian Hardy, M. Gerard Waters, Eseng Lai
  • Process for assessing oocyte and embryo quality
    Patent number: 5541081
    Abstract: Methods and compositions for assessing the quality of an oocyte or pre-implantation embryo are provided. The methods involve comparing the NADH fluorescence of the oocyte or embryo in a control medium to the NADH fluorescence after the oocyte or embryo has been contacted with an essential nutrient.
    Type: Grant
    Filed: March 22, 1994
    Date of Patent: July 30, 1996
    Assignees: President and Fellows of Harvard College, Brigham and Women's Hospital, Inc.
    Inventors: R. Ian Hardy, David E. Golan, John D. Biggers